Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Collyar: What's In It for Patients?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Varsha Gandhi, PhD, on Ibrutinib

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Nov
30
Today In Oncology
FDA Approves Durvalumab With FLOT for Resectable Gastric-GEJ Adenocarcinoma
AI Simplifies Patients Comprehension of CT Reports But Are Errors Possible
External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer
No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer
ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo